The_DT
human_JJ
myelomonocytic_JJ
cell_NN
line_NN
U-937_NN
as_IN
a_DT
model_NN
for_IN
studying_VBG
alterations_NNS
in_IN
steroid-induced_JJ
monokine_NN
gene_NN
expression_NN
:_:
marked_JJ
enhancement_NN
of_IN
lipopolysaccharide-stimulated_JJ
interleukin-1_NN
beta_NN
messenger_NN
RNA_NN
levels_NNS
by_IN
1,25-dihydroxyvitamin_NN
D3_NN
._.

The_DT
active_JJ
metabolite_NN
of_IN
vitamin_NN
D_NN
,_,
1,25-dihydroxyvitamin_NN
D3_NN
-LCB-_-LRB-
1,25_CD
-_:
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
-RCB-_-RRB-
,_,
is_VBZ
a_DT
potent_JJ
regulator_NN
of_IN
human_JJ
monocyte\/macrophage_NN
function_NN
in_FW
vitro_FW
._.

To_TO
establish_VB
a_DT
model_NN
for_IN
1,25_CD
-_:
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
regulation_NN
of_IN
human_JJ
monocyte_NN
monokine_NN
synthesis_NN
,_,
three_CD
human_JJ
cell_NN
lines_NNS
-LRB-_-LRB-
U-937_NN
,_,
THP-1_NN
,_,
and_CC
HL-60_NN
-RRB-_-RRB-
were_VBD
examined_VBN
for_IN
:_:
1_LS
-RRB-_-RRB-
the_DT
presence_NN
of_IN
functional_JJ
1,25_CD
-_:
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
receptors_NNS
;_:
2_LS
-RRB-_-RRB-
the_DT
accumulation_NN
of_IN
interleukin-1_NN
beta_NN
-LRB-_-LRB-
IL-1_NN
beta_NN
-RRB-_-RRB-
mRNA_NN
and_CC
IL-1_NN
beta_NN
protein_NN
in_IN
response_NN
to_TO
lipopolysaccharide_NN
-LRB-_-LRB-
LPS_NN
-RRB-_-RRB-
;_:
and_CC
3_LS
-RRB-_-RRB-
the_DT
regulation_NN
of_IN
this_DT
response_NN
by_IN
1,25_CD
-_:
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
._.

All_DT
three_CD
cell_NN
lines_NNS
expressed_VBD
vitamin_NN
D_NN
receptor_NN
and_CC
had_VBD
increased_VBN
levels_NNS
of_IN
IL-1_NN
beta_NN
mRNA_NN
in_IN
response_NN
to_TO
LPS_NN
._.

Preincubation_NN
of_IN
cells_NNS
with_IN
1,25_CD
-_:
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
augmented_VBD
IL-1_NN
beta_NN
mRNA_NN
levels_NNS
only_RB
in_IN
U-937_NN
and_CC
HL-60_NN
cells_NNS
._.

From_IN
these_DT
data_NNS
,_,
and_CC
taking_VBG
into_IN
consideration_NN
their_PRP$
state_NN
of_IN
differentiation_NN
and_CC
relative_JJ
ease_NN
of_IN
culture_NN
,_,
U-937_NN
was_VBD
chosen_VBN
over_IN
HL-60_NN
and_CC
THP-1_NN
as_IN
the_DT
cell_NN
line_NN
we_PRP
further_RB
characterized_VBN
._.

In_IN
U-937_NN
cells_NNS
,_,
optimum_JJ
time_NN
and_CC
dose_NN
of_IN
pretreatment_NN
with_IN
1,25_CD
-_:
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
were_VBD
determined_VBN
to_TO
be_VB
12-24_CD
h_NN
at_IN
a_DT
receptor_NN
saturating_JJ
concentration_NN
of_IN
1,25_CD
-_:
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
-LRB-_-LRB-
10_CD
nM_NN
-RRB-_-RRB-
._.

Preincubation_NN
of_IN
cells_NNS
with_IN
1,25_CD
-_:
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
had_VBD
no_DT
effect_NN
on_IN
the_DT
time_NN
course_NN
of_IN
IL-1_NN
beta_NN
mRNA_NN
appearance_NN
in_IN
response_NN
to_TO
LPS_NN
._.

However_RB
,_,
exposure_NN
of_IN
U-937_NN
cells_NNS
to_TO
1,25_CD
-_:
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
2D3_NN
increased_VBD
by_IN
200_CD
%_NN
the_DT
level_NN
of_IN
IL-1_NN
beta_NN
mRNA_NN
detected_VBN
and_CC
decreased_VBD
by_IN
three_CD
orders_NNS
of_IN
magnitude_NN
the_DT
concentration_NN
of_IN
LPS_NN
required_VBN
to_TO
achieve_VB
steady_JJ
state_NN
mRNA_NN
levels_NNS
equivalent_JJ
to_TO
those_DT
observed_VBN
in_IN
U-937_NN
cells_NNS
not_RB
preincubated_VBN
with_IN
the_DT
hormone_NN
.2_NN
+_CC
o_NN

